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What is known and what this paper adds 
What is already known? 
The incidence of chronic fatigue syndrome (CFS, also known as ME) and fibromyalgia (FM) in the UK 
population has not been recently or reliably quantified. Changing trends in the incidence of CFS/ME 
and FM in the UK during 1990-2001 were attributed largely to changing diagnostic fashions. We 
know that social adversity is associated with increased risk of CFS/ME in children and young people, 
but evidence for an association between socioeconomic status and CFS/ME in adults is less 
consistent. 
What this study adds: 
The incidence of CFS/ME diagnoses declined during 2001-2013, whereas FM diagnoses (after an 
initial decline) showed an overall increase. FM diagnoses increased markedly from 2007 onwards, 
levelling off in 2011-2013 at an annual rate of 40 per 100,000, approximately 3 times higher than 
the rate of CFS/ME diagnoses. Diagnoses of CFS/ME showed a strong social gradient, with lowest 
rates in the bottom (most deprived) socioeconomic quintile, whereas FM diagnoses had lower rates 
in the top (least deprived) quintile. 
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ABSTRACT 
Objective 
Trends in recorded diagnoses of chronic fatigue syndrome (CFS, also known as ‘myalgic 
encephalomyelitis’ (ME)) and fibromyalgia (FM) in the UK were last reported more than 10 years 
ago, for the period 1990-2001. Our aim was to analyse trends in incident diagnoses of CFS/ME and 
FM for the period 2001-2013, and to investigate whether incidence might vary by index of multiple 
deprivation (IMD) score. 
Design & setting 
Clinical Practice Research Datalink (CPRD) primary care medical record data for the period 
01/01/2001 to 31/12/2013 were analysed to obtain rates for incident diagnoses of CFS/ME and FM 
in England. We also investigated incident diagnoses of post-viral fatigue syndrome (PVFS), 
asthenia/debility (A/D), and fatigue symptoms. 
Results 
The overall annual incidence of recorded cases of CFS/ME was 14.8 (95% CI 14.5, 15.1) per 100,000 
people. Overall annual incidence per 100,000 people for FM was 33.3 (32.8-33.8), for PVFS 12.2 
(11.9, 12.5), and for A/D 7.0 (6.8, 7.2). Annual incidence rates for CFS/ME diagnoses decreased from 
17.5 (16.1, 18.9) in 2001 to 12.6 (11.5, 13.8) in 2013 (annual percent change -2.8% (-3.6%, -2.0%)). 
Annual incidence rates for FM diagnoses decreased from 32.3 (30.4, 34.3) to 27.1 (25.5, 28.6) in 
2007, then increased to 38.2 (36.3, 40.1) per 100,000 people in 2013. Overall annual incidence of 
recorded fatigue symptoms was 2246 (2242, 2250) per 100,000 people. Compared with the least 
deprived IMD quintile, incidence of CFS/ME in the most deprived quintile was 39% lower (incidence 
rate ratio (IRR) 0.61 (0.50, 0.75)), whereas rates of FM were 40% higher (IRR 1.40 (0.95, 2.06)). 
Conclusion 
These analyses suggest a gradual decline in recorded diagnoses of CFS/ME since 2001, and an 
increase in diagnoses of fibromyalgia, with opposing socioeconomic patterns of lower rates of 
CFS/ME diagnoses in the poorest areas compared with higher rates of FM diagnoses. 
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INTRODUCTION  
Chronic fatigue syndrome (CFS, also known as myalgic encephalomyelitis (ME)) and fibromyalgia 
(FM) are chronic diseases that share superficial similarities, including unknown aetiology and 
pathophysiology, varied symptomatology, a wide range of severity, higher incidence in women, no 
laboratory test to confirm diagnosis (only to rule out other diagnoses), and specific comorbidities.
1, 
2
 Three quarters of FM patients report being fatigued,
3
 and one fifth of adult and paediatric CFS/ME 
patients report widespread pain.
4
 Both diseases are debilitating, typically imposing substantial 
burdens on patients, carers and families.
5, 6
 
Seven case definitions for CFS/ME have been used internationally in clinical practice and research 
since the first was published in 1988, and these definitions have differed mainly in the minimum 
duration of fatigue and the type and number of additional symptoms.
7
 In the UK, guidelines for the 
diagnosis and management of CFS/ME were published by the National Institute for Health & Care 
Excellence (NICE) in 2007.
8
 These define CFS/ME as persistent and/or recurrent fatigue of ≥4 
months’ duration, of new or specific onset (not lifelong), characterized by post-exertional malaise, 
unexplained by other conditions, and accompanied by at least one of a dozen symptoms, including 
sleep-wake perturbations, cognitive dysfunction, and muscle and/or joint pain. Referral to specialist 
CFS/ME care should be offered within 6 weeks for children and young people, within 3-4 months 
for adults with moderate symptoms, and immediately for people with severe symptoms. NHS 
specialist CFS/ME services in England offer patient-centred programmes aiming to rehabilitate 
patients by increasing physical, emotional and cognitive capacities, whilst managing the impact of 
symptoms.
8
 
By contrast, there are as yet no UK national guidelines for FM. Criteria defining FM were published 
in 1990 by the American Royal College of Rheumatology.
9
 These were not intended to be used in 
clinical practice, and the criteria were modified in 2011 to improve their clinical utility.
10
 In essence, 
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FM should be considered in any patient reporting chronic multifocal or diffuse pain that is not 
explained by injury, inflammation or other conditions.
11
  Care pathway recommendations for FM 
patients in England have only recently been published, by the British Pain Society.
12
 These focus on 
non-specialist (primary care) management of FM, with referral to specialist care reserved for 
severely-affected patients who do not respond to treatment. As with CFS/ME, treatment options 
tend towards therapies such as Cognitive Behavioural Therapy (CBT). Pharmacological treatments 
approved in the USA for treatment of FM do not have UK approval for FM.
11
  
Trends in the incidence of CFS/ME and FM diagnoses in the UK were last reported for the period 
1990 to 2001, at the end of which there were approximately 15 CFS/ME and 35 FM cases recorded 
per 100,000 people.
13
 Incidence of FM increased dramatically from the mid-1990s to 2001, and 
CFS/ME increased from 9% to 26% of all fatigue diagnoses. Trends in the incidence of CFS/ME 
diagnoses might be expected to have changed since 2001, because of growing awareness and 
recognition of CFS/ME as a legitimate disease, and publication of NICE guidelines. The aim of the 
present study was to use nationally-representative primary care data to investigate trends in 
recorded diagnoses of CFS/ME and FM in England between 2001 and 2013, together with trends in 
the incidence of diagnoses related to CFS/ME – post-viral fatigue syndrome (PVFS) and 
asthenia/debility (A/D) – and presentation of fatigue symptoms at GP consultations. We also 
wanted to investigate whether primary care data would reveal variation in incidence by 
socioeconomic status, given conflicting evidence from an earlier study based on a data from 
CFS/ME specialist services in England.
14
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METHODS 
Data source 
The Clinical Practice Research Datalink (CPRD), formerly known as the General Practice Research 
Database (GPRD), is an anonymised research database aggregating medical records data from 
participating general practices across England (approximately 7% of 10,000 practices in 2012).
15
 
Practices contributing to CPRD are broadly representative of general practices in England in terms 
of practice size and geographical distribution, and the source population (approximately 4 million 
‘active’ patients, i.e. alive and registered with a GP) is broadly representative of the population of 
England in terms of age, sex, and ethnicity. GPs enter medical diagnoses and symptoms as Read 
codes, a hierarchical coding system used to record clinical information. Procedures, prescriptions, 
and referrals to secondary care are also recorded, and linkage to Hospital Episode Statistics (HES) 
data is available for around half of the participating practices. CPRD provides two sets of data 
quality criteria: ‘up-to-standard’ (UTS) time for practices and ‘acceptability’ for patients. These 
criteria do not ensure data quality, but the CPRD recommends that these measures are used as a 
first step to selecting research-quality patients and periods of quality data recording. The UTS date 
is a practice-based quality metric based on the continuity of recording and the number of recorded 
deaths. The acceptable patient metric is based on registration status, recording of events in the 
patient record, and valid age and gender. Patients with non-contiguous records or poor data 
recording, which thereby raises suspicion about the validity of that patient’s record, are excluded. 
For this study, data were obtained from the 660 general practices in England in the CPRD from 
01/01/2001 to 31/12/2013 whose recording of data was judged to be UTS, in order to provide a 
stable denominator for calculating incidence rates. The study protocol was approved by the MHRA 
Independent Scientific Advisory Committee (protocol #14_041R). 
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Study cohort 
Diagnoses 
Patients were identified by Read code (Supplementary Table 1) as having an event – chronic fatigue 
syndrome (CFS/ME), fibromyalgia (FM), post-viral fatigue syndrome (PVFS), or asthenia/debility 
(A/D) diagnosis or referral to a CFS/ME specialist service – during the study period (01/01/2001 to 
31/12/2013). The ‘index event’ was the earliest event of interest for a patient during the study 
period and within the practice’s UTS period and the patient’s UTS registration period. Patients were 
required to have at least 12 months of UTS data prior to the index event. For the purpose of 
estimating incidence rates, we considered incident, i.e. ‘new’, diagnoses to be those index events 
for which there was no preceding diagnosis of CFS/ME, FM, PVFS or A/D in the patient’s CPRD 
medical record. Read codes for referral to specialist services were introduced in 2010. Diagnoses 
which were made after a referral and which occurred within the patient’s UTS period (and for 
which there was no prior diagnosis) were treated as incident diagnoses. 
 
Fatigue symptoms 
Patients were identified as having presented with fatigue if they had one or more events (per 
calendar year) with a Read code for a fatigue symptom during the study period (Supplementary 
Table 1). Events must have occurred during the patient’s registration period and during the practice 
UTS period, and patients were required to have at least 12 months of UTS data prior to the event. 
 
Practice-level socioeconomic status 
The Index of Multiple Deprivation (IMD) score was used as a measure of socioeconomic status for 
the practice, based on its postcode. The IMD is the UK government’s official measure of 
deprivation.
16
 It is a composite score derived from seven domains: income, employment, health 
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and disability, education skills and training, barriers to housing and services, crime and disorder, 
and living environment. 
 
Statistical analyses 
Annual incidence rates (and 95% confidence intervals (CIs)) of diagnoses and fatigue symptoms 
were calculated by summing the number of events during each calendar year per practice, dividing 
by the number of acceptable patients registered during the corresponding year, and then 
calculating an overall rate and 95% CI per 100,000 patients. ‘Lewis plots’ were used to verify that 
requiring patients to have at least 12 months of UTS data prior to the index event had removed the 
excess events which tend to occur shortly after a patient has registered with a practice.
17
 Trends 
were analysed using join point (segmented) regression software (Joinpoint Regression Program, 
Version 4.3.1.0 - April 2016; Statistical Methodology and Applications Branch, Surveillance Research 
Program, National Cancer Institute), which performs segmented regression to estimate the annual 
percent change (APC) in incidence rates and the number and location of join points (points at which 
trends change).
18
 Join point software performs pairwise comparisons of models differing by one 
join point to determine the model with optimum fit to the data series. We allowed a maximum of 
three join points (because we had 13 data points in our analysis), and an overall significance level of 
5% was adopted for the comparisons of models applied to each data series. The models incorporate 
variation using the standard error of the rate; APC for each segment are estimated by fitting a 
regression line to the natural logarithm of the rate, using calendar year as an independent 
variable.
19
 We calculated incidence rates stratified by sex, age group and IMD quintile, and we used 
multivariable negative binomial regression to estimate adjusted incidence rate ratios (IRR) with sex, 
age, IMD quintile, and calendar year as independent variables, and robust standard errors to 
account for clustering within practices. We included interaction terms to test for evidence of 
Page 8 of 38
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Journal of the Royal Society of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
9 
 
interaction between age, sex, and IMD quintile with time, using calendar year as a continuous linear 
variable if join point had indicated a constant trend (no join point) or using time periods 
corresponding to the segments between join points. Negative binomial regression models were 
fitted using Stata (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP). We also used the Joinpoint regression software’s implementation of a statistical test 
for parallelism to test for differences in trends by age, sex and IMD quintile, using sex = female, age = 
40-49 years, and IMD = middle quintile (Q3) as reference level.
20
 
 
RESULTS 
Diagnoses and referral events 
From the source population in CPRD, 63,683 patients were deemed to have acceptable data and 
had at least one diagnostic index event during the study period. Of these patients, 48,663 had the 
event(s) within the practice UTS period, of whom 42,316 patients had at least 12 months of UTS 
data prior to the index date. FM accounted for half of the diagnoses (49.6%), followed by CFS/ME 
(23.1%), PVFS (16.3%) and A/D (9.9%) (Figure 1).  
 
There were 1,196 referrals (for 933 patients) recorded since the relevant Read codes for referral to 
specialist CFS/ME services were introduced (2010), of which 506 were index events. Of these, 11 
(2.2%) coincided with a CFS/ME diagnosis and 192 (36.9%) led to a diagnosis during the patient’s 
UTS period: 169/192 (88.0%) CFS/ME; 17/192 (8.9%) FM; 6/192 (3.1%) PVFS) (Figure 1). 
 
Diagnoses and referrals, preceding events (during the first 12 months of the UTS period or 
predating the start of the UTS period), and time between earliest preceding event (if any) and the 
index diagnosis or referral, are summarized in Table 1. Overall, 81.9% (34,677/42,316) of patients 
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had no previously recorded diagnosis of CFS/ME, PVFS, A/D or FM or referral to CFS/ME service in 
their medical record, and 12.5% (5276/42316) had a previous event of the same type as the index 
event. The remaining 2363 patients (5.6%) had at least one prior event of a different type to the 
index event. Lewis plots indicated a constant rate of diagnoses from the 13
th
 month of the UTS 
period onwards (Supplementary Figure 1). 
 
Trends in incidence of diagnoses 
The average annual incidence of recorded cases of CFS/ME over the whole study period was 14.8 
(95% CI 14.5, 15.1) per 100,000 people; for FM, the annual rate per 100,000 people was 33.3 (32.8, 
33.8); for PVFS 12.2 (11.9, 12.5), and for A/D 7.0 (6.8, 7.2). Trends in incidence rates of diagnoses 
are illustrated in Figure 2 (see Supplementary Table 2 for incidence rates). Annual incidence of 
CFS/ME decreased from 17.5 (16.1, 18.9) in 2001 to 12.6 (11.5, 13.8) in 2013. Annual incidence of 
FM decreased from 32.3 (30.4, 34.3) in 2001 to 27.1 (25.5, 28.6) in 2007, and then increased to 38.2 
(36.3, 40.1) per 100,000 people in 2013. CFS/ME as a percentage of all fatigue diagnoses (excluding 
FM) increased from 31.1% in 2001 to 59.9% in 2013, whilst A/D declined from 24.8% to 4.8% and 
PVFS declined from 41.1% to 35.4% (Supplementary Figure 2). 
 
Join point regression analysis indicated constant (no join point) trends over the study period (2001-
2013) as having the best fit to CFS/ME and PVFS incidence rates. The annual percent change (APC) 
for CFS/ME was -2.8% (95% CI -3.6%, -2.0%) and -7.8% (-10.1%, -5.5%) for PVFS (Table 2). Trends in 
diagnoses of A/D and FM each had a best fitted model with one join point: A/D diagnoses increased 
to 2003 and then declined steeply, at -29.6% (-33.9%, -24.9%) per annum; FM diagnoses decreased 
to 2007 (APC -2.4% (-5.3%, 0.7%)) and then increased by 5.9% (3.1%, 8.8%) per annum to 2013. 
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Trends in incidence of fatigue symptoms 
Overall annual incidence of recorded fatigue symptoms was 2246 (2242 to 2250) per 100,000 
people (Figure 3). The incidence of recorded fatigue symptoms increased from 2001 to 2004 (APC 
5.3% (1.1%, 9.6%)) (Table 2), with the trends in the two subsequent intervals having confidence 
intervals which do not exclude a constant rate (APC = 0 at α=0.05). 
 
Diagnoses and symptoms by age, sex and practice-level socioeconomic status 
All diagnoses showed strong evidence of variation by age and sex, and all except A/D showed 
evidence of variation across practice-level quintiles socioeconomic status (Table 3). Incidence rates 
were higher amongst women, and tended to peak between ages 30-59 years (Figure 4). Incidence 
rates of CFS/ME were 2.4-fold higher among women (incidence rate ratio (IRR) 2.35 (95% CI 2.19, 
2.53)), with peak incidence in the 40-49 years age group (IRR 1.64 (1.48, 1.83), compared with <20 
years age group). Women had 6-fold higher incidence of FM (IRR 6.13 (5.50, 6.82)), peaking 
between ages 40-49 years (IRR 25.3 (20.6, 31.1), compared with ages <20 years). Social patterns 
were in the opposite directions for CFS/ME and FM, with CFS/ME incidence being lowest and FM 
incidence tending to be higher in the two most deprived IMD quintiles (Figure 5). The incidence 
rate ratios comparing the bottom (most deprived) versus the top (least deprived) IMD quintile were 
IRR 0.61 (0.50, 0.75) for CFS/ME, IRR 1.40 (0.95, 2.06) for FM (Table 3). 
 
There were no interactions (all P≥0.2) between age, sex, IMD and CFS/ME diagnostic incidence. 
However, there was weak evidence (test for parallelism P≤0.1) of a less steep downward trend in 
CFS/ME incidence in male compared with female patients, and in age groups 20-29 years and 30-39 
years compared with 40-49 years (Figure 6, Supplementary Table 3). CFS/ME incidence in patients 
age <20 years followed a different trend to other age groups (P<0.001), decreasing from 2001-2006, 
then increasing from 2006-2011. There was strong evidence of interaction (P<0.001) between age 
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and FM incidence and between sex and FM incidence, but there was no interaction with IMD 
(P=0.2). The pattern of a pre-2007 decrease followed by a post-2007 increase was evident only 
among female patients, with male patients instead showing a steady decline (test for parallelism 
P=0.002) (Figure 6, Supplementary Table 4). Similarly, the pre-/post-2007 pattern was apparent 
among patients in the 30-39, 40-49 and 50-59 year age groups, whereas there was a constant 
increase (no join point) in incidence in patients aged <20 and 20-29 years and a constant decrease 
in incidence in patients age 60-69 and 70+ years. 
 
DISCUSSION 
Statement of principal findings 
Our study has shown that incidence of CFS/ME diagnoses declined over the period 2001-2013, 
whereas FM diagnoses (after an initial decline) showed an overall increase. Asthenia and debility 
(A/D) became almost extinct as diagnostic labels, having begun the decade on a par with CFS/ME. 
Diagnoses of PVFS also fell steeply, to one third of the incidence in 2001. Clearly, the decline in A/D 
and PVFS diagnoses did not translate into an increase in CFS/ME diagnoses. We had anticipated a 
change in overall trends in CFS/ME diagnoses after the publication of NICE guidelines in 2007, but 
none was apparent (although cases in patients <20 years-old increased from 2006 to 2011). FM 
diagnoses increased markedly from 2007 onwards, levelling off from 2011-2013 at an annual 
incidence rate of 40 per 100,000. This is roughly 3 times higher than the incidence of CFS/ME. As 
expected, incidence rates of CFS/ME and FM were higher amongst women and peaked between 
ages 30-59 years. Incidence of CFS/ME showed a strong social gradient, with lowest incidence in the 
bottom (most deprived) socioeconomic quintile, whereas FM had lower incidence in the top (least 
deprived) quintile. 
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Strengths and limitations of the study 
The main strength of our study is that it uses CPRD data, comprising the medical records of 
approximately 4 million ‘active’ patients (alive and registered with a GP), or 7% of the UK 
population.
15
 CPRD patients are representative of the UK population, and the data are subject to 
external and internal quality control. Active patients have a median of 9.4 years (IQR 3.4-13.9) of 
data,
15
 which gives us some (but not absolute) confidence in classifying diagnoses as ‘incident’ if the 
patient’s medical record has no previously recorded diagnoses. 
One limitation of our study is that we examined recorded data rather than actual incidence, i.e. we 
are describing incidence rates of GPs’ recording of diagnostic codes.  This will have missed cases not 
recognised by the GP, recognised but not entered into the clinical records, and recognised but 
entered into the records as free text. Another limitation is that diagnoses were not independently 
validated. We know from studies in specialist services that CFS/ME is frequently misdiagnosed in 
primary care.
21
  In 2005, 48% of GPs in one English region did not feel confident about making a 
diagnosis of CFS/ME and 28% did not recognize CFS/ME as a legitimate illness.
22
 Although 
knowledge and awareness of CFS/ME in primary care had improved towards the end of our study 
period,
23
 non-specialist clinicians still experienced difficulty and lack of confidence in making a 
diagnosis of CFS/ME.
24
 
Our data do not tell us whether diagnoses were made by GPs, or recorded in patients’ medical 
records following a specialist consultation. Read codes for referral to specialist services were only 
introduced in 2010, limiting our ability to explore this aspect of the CFS/ME diagnostic pathway. 
However, our estimated incidence of new CFS/ME diagnoses for the period 2008-2010 (in 2009, 
14.5 (95% CI 13.6 to 15.8) per 100,000) is not inconsistent with estimates based on data from NHS 
specialist CFS/ME services in England (in 2009, 22 (95% CI 17 to 29) per 100,000), if we consider 
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that the latter figure includes re-referrals.
14
 Incidence of CFS/ME diagnoses in 2009 from our data, 
including patients who had a previously-recorded CFS/ME diagnosis, is 17.0 (95% CI 15.8 to 18.3). 
This consistency with estimates from clinical services would suggest that the majority of patients 
who have a CFS/ME diagnosis recorded by their GP have had this diagnosis made or confirmed by a 
specialist service. Our overall annual incidence rate estimate of 14.8 (95% CI 14.5 to 15.1) per 
100,000 is also consistent with a rate of 15 (95% CI 6 to 41) per 100,000 reported for the period 
2007-2010 based on data from a primary care cross-sectional study in three English regions.
25
 These 
comparisons suggest that we can have reasonable confidence in the validity of CFS/ME diagnoses in 
CPRD records. During the early part of our study period, trends in fatigue symptoms appeared to 
parallel the underlying CPRD population denominator. This suggests a degree of artefact, for which 
we could find no explanation. Similarly, the two 'spikes' in A/D (in 2003) and PVFS (in 2009) are 
possibly artefactual, because we are not aware of any drives to enhance entry of these codes on GP 
systems.  One possible explanation for the spike in PVFS cases is the 2009 flu pandemic, which 
started in May 2009 and continued in waves until the summer of 2010.
26
 
Our study in relation to other studies 
The overall decline in ‘fatigue’ diagnoses (CFS/ME, PVFS and A/D) continues the downward trend (a 
44% decrease) reported for the period 1990-2001 using data from the same source (then called the 
General Practice Research Database (GPRD)).
13
 As in our study, this trend was set against a 
backdrop of no overall change in incidence of fatigue symptoms. This earlier study also showed the 
emergence in the mid 1990’s of fibromyalgia as a diagnosis, which the authors ascribed to fashions 
in diagnostic labelling rather than to a true increase in incidence.
13
 In addition to publication of 
NICE guidelines, the period covered by our study witnessed a growth in NHS specialist CFS/ME 
service provision across England,
27
 such that 140 of 152 Primary Care Trusts (PCTs) had 
commissioned a specialist service by 2010 (PCTs were abolished in 2013 during a reorganisation of 
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the NHS).
14
 In the context of these changes, the steady decline in CFS/ME diagnoses is perplexing. 
In the absence of curative treatments and, given that we have no reason to suspect underlying 
trends in the causal agents and risk factors for CFS/ME (or PVFS), we cannot discount a trend in 
diagnostic labelling. However, the decline does not show any sudden fluctuations, and does not 
correlate with declines in alternative diagnoses (PVFS and A/D), suggesting that it may reflect a real 
trend. 
Although specialist service provision for paediatric CFS/ME in England is geographically much less 
comprehensive than for adults, with many barriers to accessing the few available services,
28
 the 
prognosis for natural recovery in children and young people is better than in adults.
29
 Also, 
guidelines for the management of paediatric CFS/ME were published by the Royal College of 
Paediatrics and Child Health in 2004.
30
 We note that the observed annual incidence for patients <20 
years of age (10 per 100,000) translates into a prevalence of 1-2% (if we assume an average 12-24 
months’ duration of illness), which is entirely consistent with paediatric CFS/ME prevalence 
estimates from population-based studies.
31
 
We would expect that a substantial proportion (if not all) PVFS cases should have been classified as 
CFS/ME. Viral infections are known to trigger CFS/ME,
32
 and fatigue of ≥4 months’ duration after 
the acute phase of an infection has passed should, according to NICE criteria, warrant consideration 
for a diagnosis of CFS/ME.
8
 Towards the end of our study period, this reclassification would 
increase the incidence of CFS/ME by around 50%, but the trend in CFS/ME diagnoses would still be 
downwards. Population-wide incidence of CFS/ME in Norway from 2008-2012 as indicated by ICD-
10 code G93.3 (‘postviral fatigue syndrome/benign myalgic encephalomyelitis’) was 25.8 (25.2, 
26.5) per 100,000 person years.
33
 This is 74% higher than the incidence in our study, possibly 
because the ICD-10 code combines PVFS and CFS/ME in a single classification. 
Page 15 of 38
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Journal of the Royal Society of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
16 
 
Whether the levelling out of incident FM diagnoses towards the end of our study period represents 
a plateau reflecting true incidence remains to be seen. The 3-fold higher incidence of FM compared 
with CFS/ME is supported by prevalence estimates, which show that the prevalence of FM (1-5%, 
depending on classification criteria)
34
 is several times higher than the prevalence of CFS/ME (0.8% 
(95% CI 0.2% to 1.3%) from a meta-analysis of prevalence studies based on clinically-confirmed 
cases).
35
 In adults, both are long-term conditions with poor prognosis and limited therapeutic 
options.
36, 37
 The evidence-base for CFS/ME therapies is arguably stronger than for FM,
1
 but a range 
of pharmacological agents are available (albeit unsupported by strong evidence of effect) for 
symptom control in FM.
11, 38
 These include three drugs approved in the USA during the period of 
our study (pregabalin in 2007, duloxetine in 2008, and milnacipran in 2009). The absence of UK 
approval for these drugs means that we cannot ascribe the post-2007 increase in FM incidence to 
GP’s being more willing to diagnose FM because of the availability of prescription drugs for FM. 
The age and sex distributions of CFS/ME and FM are well-documented,
1, 3, 33, 34
 socioeconomic 
variation less so. We know that childhood social adversity increases the risk of CFS/ME in children 
and adolescents,
31
 and that this increased risk may persist into adulthood.
39
 Evidence for a link 
between social adversity in adulthood and risk of CFS/ME is perhaps less convincing, more likely to 
be confounded by variation in risk e.g. across ethnic groups, and more susceptible to selection bias 
e.g. by access to health care, but the overall pattern suggests higher risk among lower 
socioeconomic groups. In an analysis of patient postcode data from seven CFS/ME specialist 
services in England, we showed that assessment rates in three of the services were 39-44% lower in 
the bottom (most deprived) compared with the top (least deprived) IMD quartiles,
14
 which is 
consistent with the 39% lower diagnostic incidence that we reported, comparing the bottom with 
the top IMD quintile. There was no social pattern in the other four services, a discrepancy which we 
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attributed partly to variation in the ethnic minority composition of the communities served by the 
services. Obstacles to accessing specialist care provide the most likely explanation for decreasing 
CFS/ME diagnostic incidence with increasing social deprivation, if we assume that the well-
documented difficulties experienced by people seeking diagnosis and/or specialist treatment for 
CFS/ME are more acute for people who have limited resources.
6, 23, 28
  
That FM diagnoses showed the opposite trend requires a different explanation, although we note 
that the social pattern was for the top (least deprived) quintile to have lower incidence than the 
other four quintiles, each of which had similar incidence with only weak evidence for the bottom 
(most deprived) quintile having the highest incidence. As with CFS/ME, evidence suggests higher 
risk of pain disorders such as FM among lower social classes.
40, 41
 One possible explanation for the 
different pattern seen for FM compared with CFS/ME could be that FM is more likely to be 
diagnosed and managed within the primary care setting; not because GPs are more confident about 
diagnosing and managing FM, but because there ar  no specialist services. Indeed, the British Pain 
Society care pathway recommends primary care management of FM, with referral to specialist care 
only for severely-affected patients who do not respond to treatment.
12
 Another explanation could 
be that GPs respond more decisively to the defining symptom of FM (pain) in patients who are 
likely to be presenting with other symptoms and comorbidities,
40
 whereas the cardinal symptoms 
of CFS/ME present a more complex and less specific diagnostic picture, further complicated by 
CFS/ME-related comorbidities such as pain and mood disorders.
4
 This argument is strengthened by 
the observation that patients with FM and lower SES reported greater symptom severity and 
functional impairment,
42
 although this pattern has also been observed in community-based 
samples of people diagnosed with CFS/ME.
43
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Unanswered questions and future research 
The strong evidence for a social gradient in CFS/ME diagnoses, contrary to evidence indicating that 
incidence should if anything be higher at lower socioeconomic levels, raises a question which can 
perhaps only be answered by collecting prospective data at primary care level, supplemented by 
qualitative research into the diagnostic and referral process for patients across diverse social and 
ethnic groups. Most CFS/ME specialist services report anecdotally that black and minority ethnic 
groups are underrepresented among their service users, despite CFS/ME possibly being more 
prevalent in UK ethnic minorities,
44
 but the extent to which this disparity reflects differences in 
cultural norms or professional practice is unknown.
45
 This aspect of CFS/ME care provision requires 
investigation, something which should become possible as collection of ethnicity data within CPRD 
improves.
46
 
 
Conclusions 
Our study has provided an up-to-date picture of trends in the incidence of CFS/ME and FM 
diagnoses, indicating an ongoing need to provide care pathways and commission specialist services 
for these relatively common and debilitating long-term conditions. In addressing this need, two 
salient features of our findings need to be taken into account, namely: 1) that the incidence of FM 
is three times higher than incidence of CFS/ME, yet there are no national guidelines for the 
diagnosis and management of FM; and 2) that the incidence of CFS/ME diagnoses appears to be 
40% lower in the most versus least deprived socioeconomic quintile, despite evidence that CFS/ME 
should be as common, if not more common, among people experiencing higher levels of social 
adversity. 
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Figure Legends: 
Figure 1: CPRD patient inclusion flowchart for this study 
Figure 2: Trends in recorded diagnoses of chronic fatigue syndrome (CFS/ME), fibromyalgia, post-
viral fatigue syndrome (PVFS) and asthenia/debility (2001 – 2013) (vertical bars indicate 95% CI) 
Figure 3: Trends in fatigue symptoms (2001 – 2013) (vertical bars indicate 95% CI) 
Figure 4: Recorded diagnoses of chronic fatigue syndrome (CFS/ME), fibromyalgia, post-viral fatigue 
syndrome (PVFS) and asthenia/debility by age (vertical bars indicate 95% CI) 
Figure 5: Recorded diagnoses of chronic fatigue syndrome (CFS/ME), fibromyalgia, post-viral fatigue 
syndrome (PVFS) and asthenia/debility by Index of Multiple Deprivation (IMD) quintile (vertical bars 
indicate 95% CI) 
Figure 6: Trends in recorded diagnoses of chronic fatigue syndrome (CFS/ME) and fibromyalgia 
(2001 – 2013) by sex, age, and Index of Multiple Deprivation (IMD) quintile 
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Table 1: Index events (diagnoses and referrals recorded during the study period, 2001-2013)
†
 
  Preceding events 
Index event (diagnosis or referral) Frequency None A/D only CFS/ME only FM only PVFS only Referral only Any
‡
 
Asthenia and debility (A/D) 4199 3699 (88.1%) 459 (10.9%) 10 (0.2%) 6 (0.1%) 18 (0.4%) 0 (0.0%) 7 (0.2%) 
Time from earliest preceding event to index event, median (IQR) years 5 (3 – 8) 5 (3 – 9) 6 (4 – 8) 9 (6 – 14) - 7 (5 – 12) 
CFS/ME 9946 7199 (72.4%) 56 (0.6%) 1556 (15.6%) 67 (0.7%) 388 (3.9%) 7 (0.1%) 673 (6.8%) 
Time from earliest preceding event to index event, media  (IQR) years 10 (6 – 14) 5 (2 – 10) 5 (3 – 7) 9 (4 – 13) 1 (0 – 10) 6 (1 – 11) 
Fibromyalgia (FM) 20984 17,157 (81.8%) 134 (0.6%) 241 (1.1%) 2947 (14.0%) 176 (0.8%) 0 (0.0%) 329 (1.6%) 
Time from earliest preceding event to index event, median (IQR) years 11 (8 – 15) 7 (2 – 12) 4 (2 – 8) 12 (8 – 16) - 8 (4 – 12) 
Post Viral Fatigue Syndrome (PVFS) 6884 6368 (92.5%) 28 (0.4%) 77 (1.1%) 29 (0.4%) 311 (4.5%) 0 (0.0%) 71 (1.0%) 
Time from earliest preceding event to index event, median (IQR) years 10 (4 – 13) 6 (3 – 13) 8 (6 – 11) 8 (3 – 13) - 5 (2 – 12) 
Referral to CFS/ME service 303 254 (83.8%) 1 (0.3%) 30 (9.9%) 3 (1.0%) 3 (1.0%) 3 (1.0%) 9 (3.0%) 
Time from earliest preceding event to index event, median (IQR) years 16 8 (4 – 15) 10 (3 – 20) 24 (16 – 26) 1 (0 – 2) 4 (2 – 6) 
†
 For the purpose of estimating incidence rates, we considered incident diagnoses to be those index events for which there was no preceding diagnosis of 
CFS/ME, FM, PVFS or A/D in the patient’s CPRD medical record (Preceding events = “None”). There were 506 referral index events, of which 11 (2.2%) 
coincided with a diagnosis and 192 (36.9%) led to a diagnosis during UTS follow-up 
‡
 Any other sequence of 2 or more events (A/D, CFS/ME, FM, PVFS, referral to CFS/ME service) 
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Table 2: Trends in incidence of diagnoses and fatigue symptoms 
Diagnosis/symptoms Period 1 Annual Percent 
Change (95% CI) 
Period 2 Annual Percent 
Change (95% CI) 
Period 3 Annual Percent 
Change (95% CI) 
Asthenia and debility (A/D) 2001-2003 27.2 (-14.8, 90.0) 2003-2013 -29.6 (-33.9, -24.9)*   
CFS/ME 2001-2013 -2.8 (-3.6, -2.0)*     
Fibromyalgia 2001-2007 -2.4 (-5.3, 0.7) 2007-2013 5.9 (3.1, 8.8)*   
Post Viral Fatigue Syndrome (PVFS) 2001-2013 -7.8 (-10.1, -5.5)     
Fatigue symptoms 2001-2004 5.3 (1.1, 9.6)* 2004-2009 1.0 (-1.1, 3.3) 2009-2013 -1.7 (-3.9, 0.5) 
* Evidence that Annual Percentage Change is greater than or less than zero at α=0.05 
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Table 3: Incidence rate ratios (IRR (95% CI)) for diagnoses, referrals and symptoms (by age, sex and practice-level socioeconomic status) 
  A/D CFS/ME FM PVFS Referral Fatigue (symptom) 
Female (cf. male)  2.15 (1.94, 2.38) 2.35 (2.19, 2.53) 6.13 (5.50, 6.82) 2.01 (1.89, 2.14) 2.09 (1.48, 2.95) 2.28 (2.26, 2.31) 
Age (cf. <20) years 20 to 29 2.16 (1.66, 2.83) 0.86 (0.76, 0.96) 4.86 (4.02, 5.89) 0.66 (0.58, 0.75) 2.39 (1.43, 4.02) 2.41 (2.34, 2.48) 
 30 to 39 3.46 (2.68, 4.46) 1.39 (1.24, 1.55) 13.5 (11.0, 16.7) 1.01 (0.90, 1.14) 2.56 (1.39, 4.72) 2.33 (2.26, 2.40) 
 40 to 49 4.01 (3.03, 5.30) 1.64 (1.48, 1.83) 25.3 (20.6, 31.1) 1.22 (1.08, 1.38) 3.07 (1.82, 5.18) 2.38 (2.31, 2.46) 
 50 to 59 2.80 (2.10, 3.74) 1.31 (1.17, 1.46) 24.7 (20.2, 30.4) 0.99 (0.88, 1.11) 1.43 (0.85, 2.40) 2.47 (2.39, 2.54) 
 60 to 69 1.27 (1.02, 1.58) 0.56 (0.48, 0.65) 12.6 (10.3, 15.3) 0.57 (0.50, 0.66) 0.66 (0.32, 1.38) 2.49 (2.41, 2.57) 
 70+ 1.91 (1.47, 2.47) 0.23 (0.19, 0.27) 5.99 (4.88, 7.36) 0.51 (0.44, 0.60) 0.28 (0.12, 0.64) 3.51 (3.41, 3.62) 
Practice-level IMD quintile 
(cf. Least deprived)
†
 
Quintile 2 0.59 (0.17, 2.04) 1.00 (0.85, 1.17) 1.21 (0.94, 1.57) 0.91 (0.66, 1.25) 1.63 (0.75, 3.52) 0.98 (0.86, 1.10) 
Quintile 3 1.09 (0.30, 4.03) 1.04 (0.85, 1.26) 1.05 (0.86, 1.27) 0.80 (0.57, 1.13) 1.90 (0.87, 4.16) 0.87 (0.79, 0.96) 
 Quintile 4 0.97 (0.33, 2.80) 0.82 (0.69, 0.98) 1.24 (1.01, 1.51) 0.66 (0.50, 0.87) 1.37 (0.66, 2.85) 0.85 (0.77, 0.94) 
 Most deprived 2.30 (0.72, 7.38) 0.61 (0.50, 0.75) 1.40 (0.95, 2.06) 0.67 (0.48, 0.93) 0.97 (0.47, 2.02) 0.96 (0.86, 1.07) 
†
 Practice-level socioeconomic status was measured by its Index of Multiple Deprivation (IMD) score, divided into quintiles. IRR are adjusted for all of the 
factors shown in the table. 
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Figure 1: CPRD patient inclusion flowchart for this study  
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Figure 2: Trends in recorded diagnoses of chronic fatigue syndrome (CFS/ME), fibromyalgia, post-viral 
fatigue syndrome (PVFS) and asthenia/debility (2001 – 2013)  
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Figure 3: Trends in fatigue symptoms (2001 – 2013)  
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Figure 4: Recorded diagnoses of asthenia/debility, chronic fatigue syndrome (CFS/ME), fibromyalgia, and 
post-viral fatigue syndrome (PVFS) by age  
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Figure 5: Recorded diagnoses of chronic fatigue syndrome (CFS/ME), fibromyalgia, post-viral fatigue 
syndrome (PVFS) and asthenia/debility by Index of Multiple Deprivation (IMD) quintile  
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Figure 6: Trends in recorded diagnoses of chronic fatigue syndrome (CFS/ME) and fibromyalgia (2001 – 
2013) by sex, age, and Index of Multiple Deprivation (IMD) quintile  
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Supplementary Table 1: READ codes defining diagnoses and symptoms 
READ CODE READ TERM Type of event 
Eu46011 [X]FATIGUE SYNDROME CFS/ME 
F03y.12 MYALGIC ENCEPHALOMYELITIS CFS/ME 
F286.00 CHRONIC FATIGUE SYNDROME CFS/ME 
F286.11 CFS - CHRONIC FATIGUE SYNDROME CFS/ME 
F286.15 MYALGIC ENCEPHALOMYELITIS CFS/ME 
F286.16 ME - MYALGIC ENCEPHALOMYELITIS CFS/ME 
F286000 Mild chronic fatigue syndrome CFS/ME 
F286100 Moderate chronic fatigue syndrome CFS/ME 
F286200 Severe chronic fatigue syndrome CFS/ME 
F286.12 POSTVIRAL FATIGUE SYNDROME PVFS 
F286.13 PVFS - POSTVIRAL FATIGUE SYN PVFS 
F286.14 POST-VIRAL FATIGUE SYNDROME PVFS 
R007400 [D]POSTVIRAL (ASTHENIC) SYNDROME PVFS 
1684.13 C/O - POSTVIRAL SYNDROME PVFS 
R007411 [D]POST VIRAL DEBILITY PVFS 
Eu46000 [X]NEURASTHENIA Asthenia/Debility 
Eu46y14 [X]PSYCHASTHENIA Asthenia/Debility 
Eu46y15 [X]PSYCHASTHENIA NEUROSIS Asthenia/Debility 
E205.00 NEURASTHENIA - NERVOUS DEBILITY Asthenia/Debility 
N239.00 FIBROMYALGIA FM 
N248.00 FIBROMYALGIA FM 
8HkW.00 Referral to chronic fatigue syndrome specialist team Referral 
8HlL.00 Referral for chronic fatigue syndrome activity management Referral 
8Q1..00 Activity management for chronic fatigue syndrome Referral 
R007200 [D]ASTHENIA NOS Symptom 
R202.00 [D]SENILE ASTHENIA Symptom 
R2y3.00 [D]DEBILITY, UNSPECIFIED Symptom 
168..00 TIREDNESS SYMPTOM Symptom 
168..11 FATIGUE - SYMPTOM Symptom 
168..12 LETHARGY - SYMPTOM Symptom 
168..13 MALAISE - SYMPTOM Symptom 
1682.00 FATIGUE Symptom 
1683.00 TIRED ALL THE TIME Symptom 
1683.11 C/O - "TIRED ALL THE TIME" Symptom 
1684.00 MALAISE/LETHARGY Symptom 
1684.11 C/O - DEBILITY - MALAISE Symptom 
168Z.00 TIREDNESS SYMPTOM NOS Symptom 
E205.12 TIRED ALL THE TIME Symptom 
R007.00 [D]MALAISE AND FATIGUE Symptom 
R007000 [D]MALAISE Symptom 
R007100 [D]FATIGUE Symptom 
R007211 [D]GENERAL WEAKNESS Symptom 
R007300 [D]LETHARGY Symptom 
R007500 [D]TIREDNESS Symptom 
R007z00 [D]MALAISE AND FATIGUE NOS Symptom 
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Supplementary Table 2: Diagnostic events and rates (per 100,000), 2001-2013 
Year Denominator 
Asthenia/Debility CFS/ME Fibromyalgia PVFS 
Events Rate (95% CI) Events Rate (95% CI) Events Rate (95% CI) Events Rate (95% CI) 
2001 3222694 411 12.8 (11.5, 14.0) 564 17.5 (16.1, 18.9) 1042 32.3 (30.4, 34.3) 679 21.1 (19.5, 22.7) 
2002 3465374 548 15.8 (14.5, 17.1) 590 17.0 (15.7, 18.4) 1130 32.6 (30.7, 34.5) 640 18.5 (17.0, 19.9) 
2003 3865675 832 21.5 (20.1, 23.0) 640 16.6 (15.3, 17.8) 1305 33.8 (31.9, 35.6) 633 16.4 (15.1, 17.7) 
2004 4075970 542 13.3 (12.2, 14.4) 714 17.5 (16.2, 18.8) 1342 32.9 (31.2, 34.7) 554 13.6 (12.5, 14.7) 
2005 4301541 391 9.1 (8.2, 10.0) 654 15.2 (14.0, 16.4) 1250 29.1 (27.4, 30.7) 609 14.2 (13.0, 15.3) 
2006 4361284 365 8.4 (7.5, 9.2) 603 13.8 (12.7, 14.9) 1243 28.5 (26.9, 30.1) 509 11.7 (10.7, 12.7) 
2007 4365288 227 5.2 (4.5, 5.9) 644 14.8 (13.6, 15.9) 1181 27.1 (25.5, 28.6) 507 11.6 (10.6, 12.6) 
2008 4414083 175 4.0 (3.4, 4.6) 659 14.9 (13.8, 16.1) 1434 32.5 (30.8, 34.2) 403 9.1 (8.2, 10.0) 
2009 4434175 65 1.5 (1.1, 1.8) 651 14.7 (13.6, 15.8) 1516 34.2 (32.5, 35.9) 636 14.3 (13.2, 15.5) 
2010 4367562 47 1.1 (0.8, 1.4) 608 13.9 (12.8, 15.0) 1464 33.5 (31.8, 35.2) 364 8.3 (7.5, 9.2) 
2011 4280588 54 1.3 (0.9, 1.6) 533 12.5 (11.4, 13.5) 1672 39.1 (37.2, 40.9) 380 8.9 (8.0, 9.8) 
2012 4217212 36 0.9 (0.6, 1.1) 538 12.8 (11.7, 13.8) 1672 39.6 (37.7, 41.5) 300 7.1 (6.3, 7.9) 
2013 3976481 40 1.0 (0.7, 1.3) 503 12.6 (11.5, 13.8) 1520 38.2 (36.3, 40.1) 297 7.5 (6.6, 8.3) 
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Supplementary Table 3: Comparisons of trends in incidence of CFS/ME diagnoses by age, sex and IMD quintile
†
 
  Period 1 Annual Percent 
Change (95% CI) 
Period 2 Annual Percent 
Change (95% CI) 
Period 3 Annual Percent 
Change (95% CI) 
Test for 
parallelism 
Sex Female 2001-2013 -4.0 (-5.5, -2.4)*     Reference 
 Male 2001-2013 -2.6 (-3.4, -1.7)*     P=0.04 
Age (years) <20 2001-2006 -4.3 (-7.2, 1-.3)* 2006-2011 6.4 (2.3, 10.7)* 2011-2013 -6.5 (-17.5, 6.0) P=0.001 
 20 to 29 2001-2013 -2.9 (-4.9, --0.9)*     P=0.10 
 30 to 39 2001-2013 -2.1 (-4.1, -0.1)*     P=0.04 
 40 to 49 2001-2013 -4.2 (-5.5, -2.9)*     Reference 
 50 to 59 2001-2013 -4.2 (-5.5, -2.9)*     P=0.99 
 60 to 69 2001-2013 -3.5 (-6.3, -0.6)*     P=0.60 
 70+ 2001-2013 -4.6 (-8.8, -0.2)*     P=0.82 
Practice-level IMD quintile Least deprived 2001-2013 -3.9 (-5.3, -2.5)*     P=0.37 
 Quintile 2 2001-2013 -3.2 (-5.5, -0.8)*     P=0.72 
 Quintile 3 2001-2013 -2.9 (-4.9, -0.8)*     Reference 
 Quintile 4 2001-2013 -2.0 (-4.0, -0.1)*     P=0.54 
 Most deprived 2001-2013 -2.0 (-3.2, -0.9)*     P=0.40 
†
 Trends shown are best fit to data for individual levels of each categorical variable. Test for parallelism P-value indicates strength of evidence for departure 
from parallel trend with reference level of categorical variable 
* Evidence that Annual Percentage Change is greater than or less than zero at α=0.05. 
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Supplementary Table 4: Comparisons of trends in incidence of FM diagnoses by age, sex and IMD quintile
†
 
  Period 1 Annual Percent 
Change (95% CI) 
Period 2 Annual Percent 
Change (95% CI) 
Period 3 Annual Percent 
Change (95% CI) 
Test for 
parallelism 
Sex Female 2001-2007 -1.7 (-4.8, 1.4) 2007-2013 6.4 (3.6, 9.4)*   Reference 
 Male 2001-2013 -2.3 (-4.0, -0.5)*     P=0.002 
Age (years) <20 2001-2013 3.5 (-1.0, 8.1)     P=0.81 
 20 to 29 2001-2013 5.0 (2.3, 7.7)*     P=0.52 
 30 to 39 2001-2006 -4.4 (-9.4, 0.9) 2006-2011 10.1 (2.5, 18.3)* 2011-2013 -7.0 (-25.4, 15.7) P=0.03 
 40 to 49 2001-2007 -2.2 (-5.8, 1.6) 2007-2013 8.8 (5.5, 12.2)*   Reference 
 50 to 59 2001-2007 -2.2 (-5.4, 1.0) 2007-2013 6.0 (3.0, 9.1)*   P=0.01 
 60 to 69 2001-2013 -1.5 (-3.2, 0.3)     P<0.001 
 70+ 2001-2013 -3.4 (-5.5, -1.1)*     P<0.001 
Practice-level IMD quintile Least deprived 2001-2007 -4.7 (-7.9, -1.4)* 2007-2011 8.6 (-1.1, 19.2) 2011-2013 -8.3 (-24.0, 10.6) P=0.13 
 Quintile 2 2001-2007 -3.7 (-7.2, -0.2)* 2007-2010 10.9 (-8.0, 33.7) 2010-2013 0.6 (-7.8, 9.8) P=0.63 
 Quintile 3 2001-2013 3.0 (0.6, 5.5)*     Reference 
 Quintile 4 2001-2006 -6.7 (-11.3, -1.9)* 2006-2013 1.1 (-2.0, 4.4)   P=0.002 
 Most deprived 2001-2013 1.4 (-0.5, 3.3)     P=0.64 
†
 Trends shown are best fit to data for individual levels of each categorical variable. Test for parallelism P-value indicates strength of evidence for departure 
from parallel trend with reference level of categorical variable 
* Evidence that Annual Percentage Change is greater than or less than zero at α=0.05 
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Supplementary Figure 1: Lewis plot of incidence rates in months 13-24 of follow-up 
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Gallagher AM, Thomas JM, Hamilton WT, White PD. Incidence of fatigue symptoms 
and diagnoses presenting in UK primary care from 1990 to 2001. 
J R Soc Med. 2004;97(12):571-5       Copyright © 2004, The Royal Society of Medicine 
Supplementary Figure 2: Diagnoses of CFS/ME, fibromyalgia (FM), post viral fatigue syndrome (PVFS) and asthenia/debility 
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